Trump secures a major deal with Eli Lilly and Novo Nordisk to cut obesity drug costs as Medicare expands coverage for Zepbound and Wegovy by 2026.

President Donald Trump has unveiled a deal with drugmakers Eli Lilly and Novo Nordisk to reduce prices for their obesity treatments Zepbound and Wegovy. Here’s what we know.

President Donald Trump announces an agreement with drugmakers Novo Nordisk and Eli Lilly to lower the cost of their GLP-1 weight loss drugs Wegovy and Zepbound, a move that could make them more affordable for millions of people.

The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx.

The agreement will also secure a $150 price for future weight loss pills from Novo Nordisk and Eli Lilly—at least initially.

The Trump administration is currently negotiating with Danish pharmaceuticals, including Eli Lilly and Novo Nordisk to minimize the cost of glucagon-like peptide-1 GLP-1 drugs — weight-loss pills.Several credible sources informed ABC